Thermo Fisher Scientific Inc. – Consensus ‘buy’ rating and 8.5% Upside Potential

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Thermo Fisher Scientific Inc. which can be found using ticker (TMO) have now 24 confirmed analysts covering the stock with the consensus suggesting a rating of ‘buy’. The range between the high target price and low target price is between $670.00 and $553.00 suggesting an average Analsyt target price of $622.29. Given that the stocks previous close was at $573.64 this indicates there is a potential upside of 8.5%. The 50 day moving average now sits at $575.64 and the 200 day moving average is $531.45. The market cap for the company is 220.61B. The stock price is currently at: $577.93 USD

The potential market cap would be $239,314,483,724 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 37.05, revenue per share of $110.37 and a 4.82% return on assets.

Thermo Fisher Scientific Inc. is engaged in serving science. The Company operates through four segments. Life Sciences Solutions segment provides a portfolio of reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. Analytical Instruments segment provides an offering of instruments and the supporting consumables, software and services that are used for a range of applications. Specialty Diagnostics segment offers a range of diagnostic test kits, reagents, culture media, instruments and associated products to serve customers in healthcare, clinical, pharmaceutical, industrial and food safety laboratories. Laboratory Products and Biopharma Services segment offers virtually everything needed for the laboratory. Its brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:

      Search

      Search